---
schema_version: "secwatch.filing_event.v1"
accession: "0001651944-23-000065"
form_type: "8-K"
ticker: null
cik: "0001651944"
company_name: "DermTech, Inc."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:33:32.166410+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# DermTech: 15% workforce cut, pipeline suspended, cash runway to Q1 2025

## Summary
- Reduction of ~40 employees (~15%), completion expected by end-of-July 2023.
- Annualized cost savings of $25M-$30M; one-time charge ~$2M in Q2 2023.
- All pipeline programs suspended; focus solely on DermTech Melanoma Test revenue.
- Cash runway extended into Q1 2025; $108.4M cash as of March 31, 2023.
- Chief Commercial Officer Todd Wood to depart July 3, 2023; separation terms pending.

## SEC filing metadata
- accession: 0001651944-23-000065
- form_type: 8-K
- cik: 0001651944
- company_name: DermTech, Inc.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651944/000165194423000065/0001651944-23-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651944/000165194423000065/dmtk-20230626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651944-23-000065
- JSON: https://secwatch.observer/filing/0001651944-23-000065.json
- Plain text: https://secwatch.observer/filing/0001651944-23-000065.txt

## Key facts
- Executive change
  Todd Wood departed as chief commercial officer at DermTech, Inc..
  - Action: depart
  - Role: chief commercial officer
  source text: On June 26, 2023, it was determined that Todd Wood’s last day of employment as chief commercial officer of the Company will be July 3, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651944/000165194423000065/0001651944-23-000065-index.htm
- Restructurings & Charges
  DermTech, Inc. announced a restructuring with charges of approximately $2 million affecting sales, marketing and G&A functions (approximately 40 employees, or approximately 15%).
  - Type: restructuring
  - Charge: approximately $2 million
  - Affected area: sales, marketing and G&A functions
  - Headcount: approximately 40 employees, or approximately 15%
  source text: approximately 40 employees, or approximately 15%, and will extend the Company’s cash runway. The Company estimates that it will incur aggregate pre-tax charges of approximately $2 million in connection with the Reduction in Force, primarily consisting of severance payments, employee benefits, outplacement services and related costs. The Company expects that the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651944/000165194423000065/0001651944-23-000065-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.